Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02565017 · ClinicalTrials.gov registry record
Examining Patient Preferences About the IBM Watson Oncology Clinical Decision Support System
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 70
- Enrollment target
NCT02565017: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02565017 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 70 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02565017 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 70 participants
- Enrollment target
Study Summary
The purpose of this study is to learn what cancer patients think about IBM Watson Oncology. IBM Watson Oncology is a computer program designed to help inform oncologists about the best chemotherapy choices for their patients. The investigators will conduct focus groups with cancer patients who have received chemotherapy treatment at MSK in order to understand cancer patients' thoughts about IBM Watson Oncology.
Primary Outcome
Data collected through the brief questionnaires (e.g.,initial impressions of IBM Watson Oncology, sociodemographics) will be entered into an SPSS data file on the secure MSK server.
Interventions
- BEHAVIORAL Focus groups
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2015-09-15 |
| Est. Completion | 2020-06-22 |
What the finished NCT02565017 record still lists
NCT02565017 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 70 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Focus groups is the first listed.
NCT02565017 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02565017 about?
NCT02565017 is a clinical study titled "Examining Patient Preferences About the IBM Watson Oncology Clinical Decision Support System". The purpose of this study is to learn what cancer patients think about IBM Watson Oncology. IBM Watson Oncology is a computer program designed to help inform oncologists about the best chemotherapy choices for their patients. The investigators will conduct focus groups with cancer patients who have ...
What is the current status of trial NCT02565017?
This trial is currently completed. The enrollment target is 70 participants. The study started on 2015-09-15. Estimated completion is 2020-06-22.
What interventions are being tested in trial NCT02565017?
The interventions under investigation include: Focus groups (BEHAVIORAL).
Who is sponsoring clinical trial NCT02565017?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI